Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Net Income
Bottom-line profit after all expenses, interest, and taxes.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income remains negative
Q3 FY2026 net income was -$110.44M, compared with -$90.9M a year earlier. Trailing-twelve-month net income was -$428.73M.
Context
- Net income amounted to 4612.1% of revenue in FY2025.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$364.91M (-5.5%) for the fiscal year ending Dec 2026, a step up from the -47.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$110.44M+0.3% QoQ
- Last fiscal yearDec 2025
- -$345.91M-47.6% YoY
- LTMSep 2026
- -$428.73M-40.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -21.5% | -1.3% | +20.2 pp |
| 1 year | -47.6% | -5.5% | +42.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (345.91M) USD
- Year-over-year change
- -47.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (345.91M) | -47.6% |
| FY2024 | 2024-12-31 | (234.33M) | -28.5% |
| FY2023 | 2023-12-31 | (182.39M) | -45.5% |
| FY2022 | 2022-12-31 | (125.37M) | -58.9% |
| FY2021 | 2021-12-31 | (78.88M) | — |
Net Income vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's LTM Sep 2026 net income of -$428.73M is the 10th highest of the 11 companies compared; the peer median is -$108.58M.
- Its year-over-year change of -40.0% is the 10th highest of 11, against a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $702.5M | +64.1% | +45.8% | 19.0% | |
| LTM Sep 2026 | $362.23M | +38.7% | — | 30.1% | |
| LTM Sep 2026 | $205.95M | +155.9% | — | 4.4% | |
| LTM Dec 2025 | -$39.95M | +14.1% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$107.28M | -34.6% | — | 536.4% |
| LTM Jun 2026 | -$109.89M | -270.4% | — | 13.2% | |
| LTM Jun 2026 | -$191.64M | +22.4% | — | 24.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$222.39M | +13.8% | — | — |
| LTM Sep 2026 | -$359.43M | -31.6% | — | — | |
| LTM Sep 2026 | -$428.73M | -40.0% | — | — | |
| LTM Jun 2026 | -$511.45M | -6.8% | — | 14191.2% | |
| Peer median (excluding XENE) | -$108.58M | +13.9% | +45.8% | 24.7% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Cost of Revenue | 0 | 0 | 167.51M | 2.56M | 2.54M |
| Gross Profit | 18.44M | 9.43M | (167.51M) | (2.56M) | 4.96M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| Research & Development | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Selling, General & Admin | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| Operating Expenses | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| EBITDA | (78.09M) | (127.74M) | (210.51M) | (235.86M) | (342.35M) |
| EBITDA Margin | -423.5% | -1354.0% | — | — | -4564.7% |
| Operating Income | (78.99M) | (129.14M) | (214.05M) | (279.3M) | (373.07M) |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Income | 466K | 8.71M | 27.62M | 41.94M | 26.83M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Income Before Tax | (78.89M) | (125.26M) | (182.69M) | (238.42M) | (344.89M) |
| Pre-Tax Margin | -427.9% | -1327.7% | — | — | -4598.6% |
| Income Tax Expense | (6K) | 118K | (292K) | (4.09M) | 1.02M |
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Basic) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| EPS (Diluted) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| Weighted Avg Shares | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Weighted Avg Shares (Diluted) | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.